Rexahn reports top-line data for Archexin in pancreatic cancer

Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) reported top-line data from a single-arm, open-label Phase IIa trial in 31 patients with metastatic pancreatic cancer showing that Archexin plus gemcitabine le...